Full Breakdown
Israel’s Health Ministry Proposes Overhaul of Medical-Cannabis Regulation
5/4/2026, 11:27:44 AM
Proposed Overhaul of Medical-Cannabis Policy
A special committee chaired by Dr. Gilad Bodenheimer submitted recommendations to Health Ministry Director-General Moshe Bar Siman-Tov calling for a phased ban on smoking medical cannabis within three years. The plan would replace smoked flower with extracts or precision inhalers, lower default THC doses, require in-person prescription renewals after six months, and shift all prescribing, dispensing and monitoring to Israel’s health-maintenance organisations (HMOs).
Regulatory Background and Market Growth
Israel regulated medical cannabis in 2016 to provide a reliable supply while protecting public health. A decade later, the number of licensed patients rose from roughly 33,000 in 2019 to about 140,000 by 2024-2025, making the country one of the world’s highest per-capita consumers. Consumption is dominated by smoking: 87 % of users smoke, and 98 % of licensed purchases are for smokable products. High-THC preparations account for 88 % of licences, and 62 % of patients use more than 30 grams per month.
Key Actors in the Reform Process
- Dr. Gilad Bodenheimer – Head of the Ministry’s mental-health division and chair of the advisory committee.
- Moshe Bar Siman-Tov – Health Ministry Director-General, recipient of the committee’s report.
- Israel’s four health-maintenance organisations – slated to assume full responsibility for diagnosis, approval, dispensing and follow-up.
- Patients with PTSD, chronic pain, fibromyalgia – primary therapeutic groups highlighted in the recommendations.
Usage Data and Health Concerns
The committee flagged several risk factors:
- High-THC products are linked to a >20 % probability of developing addiction, even when used medically.
- Smoking delivers inconsistent dosing, impedes monitoring, and may encourage tobacco co-use.
- A risk questionnaire and “red-flag” protocol are proposed to identify escalating use, doctor-shopping, or concurrent addictive medication.
Official Statements from the Health Ministry and Committee
The Ministry emphasized that the reforms aim to “ensure treatment is given in the correct and safest way” while preserving access for patients with genuine need. The committee stressed that smoking “is not a legitimate medical form of treatment because dosage and absorption are inconsistent and cannot be properly monitored.” It also noted that long-term harm from cannabis is proven, whereas benefits for PTSD remain insufficiently demonstrated. Accordingly, cannabis for PTSD would be allowed only in severe distress (e.g., insomnia, flashbacks) and must be paired with psychotherapy.
Criticism and Concerns from Stakeholders
Analysts warned that the timing—just months before national elections—could provoke public backlash, especially given the market’s reliance on smoked flower. Critics also highlighted two gaps: the report does not address the leakage of medical cannabis into the gray market, and it omits specific data on teenage exposure despite a reported 27 % usage rate among people 15 and older.
Conflicting Figures and Unaddressed Issues
Sources differ on the year of the 140,000-patient count (2024 vs. 2025). Percentages of smokers are reported as 87 % of users versus 98 % of licensed purchases, reflecting different measurement bases. No source provides quantitative estimates of cannabis diversion or the scale of teenage consumption, leaving those questions unresolved.
Potential Impact on Patients and the Health System
If implemented, the reforms could reduce smoking-related health risks, improve dose precision, and integrate cannabis treatment into electronic medical records, facilitating coordinated care. Conversely, the transition may disrupt supply chains for hundreds of thousands of patients and require rapid capacity building within HMOs.
Next Steps and Timeline
- Year 1: HMOs prepare infrastructure for diagnosis, approval and dispensing.
- Three-year horizon: Complete phase-out of smokable cannabis, with limited exceptions for patients over 75 or terminally ill.
- Legislative action: The Ministry’s proposals will be submitted to the Knesset for formal approval.
Verbatim Quotes
- “We are seeing growing use of high concentrations of THC, the psychoactive component of cannabis, which produces effects that concern us,” — Dr. Gilad Bodenheimer, Head of the Ministry’s Mental Health Division
- “With an inhaler, we know exactly how much the patient inhaled, unlike flowers and smoking, where it is impossible to understand what is happening,” — Dr. Gilad Bodenheimer
- “There is a widespread belief among the public that cannabis is a magic cure, and this is not the case,” — Dr. Gilad Bodenheimer
- “Treatment will not be taken from those who need it, but it will be ensured that this treatment is given in the correct and safest way,” — Health Ministry officials
- “It must not be forgotten that to this day there is no evidence of medical benefits,” — Senior Health Ministry official
